转移性结直肠癌贝伐单抗治疗中高血压的发生情况及客观有效率

Bevacizumab-induced Hypertension and Its Treatment Response in Metastatic Colorectal Cancer

[目的]观察贝伐单抗治疗转移性结直肠癌中高血压的发生情况,评价其对贝伐单抗疗效的预测价值。[方法]回顾性分析贝伐单抗联合化疗治疗的转移性结直肠癌患者中,不良反应高血压的发生情况。根据是否发生贝伐单抗相关性高血压把患者分为两组,比较两组疾病有效率(RR)情况。[结果]64例患者中完全缓解(CR)5例(7.8%),部分缓解(PR)31例(48.4%)。使用贝伐单抗出现高血压的患者为15例,CR+PR为12例,RR为80.0%,而使用贝伐单抗未出现高血压的患者为49例,其中CR+PR为24例,RR为49.0%。两组比较差异无统计学意义(P=0.034).[结论]高血压为贝伐单抗治疗转移性结直肠癌中常见不良反应,高血压的出现有可能成为判断其疗效的较好的预测因子。

[Purpose] To investigate the occurrence of hypertension induced by bevacizumab in the treatment for metastatic colorectal cancer（mCRC） and to evaluate its value in predicting efficacy of bevacizumab. [Methods] The occurrence of bevacizumab-related hypertension in mCRC patient treated with bevacizuma combined with chemotherapy was analyzed retrospectively. Patients were divided into two groups according to the occurrence of bevacizumab-induced hypertension or not. And short term recent response rates of the two groups were compared. [Results] Of 64 cases in the 2 groups,5 cases（7.8%） were complete response（CR）,31cases（48.4%）,partial response（PR）. There were 15 cases complicated with bevacizumab-induced hypertension,with CR＋PR in 12 cases（RR 80.0%）, and 49 cases without bevacizumabinduced hypertension,with CR＋PR in 24 cases（RR 49.0%）. There was significant difference between the two groups（P=0.034）. [Conclusion]Hypertension is the common toxicity in mCRC patients treated with bevacizumab. Bevacizumab-induced hypertension might be the potential factor for predicting the effect.